Gregor Mac Mullen
About Gregor Mac Mullen
Gregor Mac Mullen serves as the Director of Technical Operations at QuVa Pharma, where he leads initiatives for process automation and oversees equipment engineering projects. His extensive background includes significant roles at Pfizer and Roche Molecular Systems, focusing on operations technology and manufacturing processes.
Current Role at QuVa Pharma
Gregor Mac Mullen serves as the Director of Technical Operations at QuVa Pharma, Inc., a position he has held since 2020. In this role, he leads strategic initiatives focused on process automation and development, aiming to enhance process robustness. He oversees equipment engineering and capital projects that are designed to increase manufacturing capacity. Additionally, he is responsible for product and project risk assessment and mitigation, ensuring that operations align with industry standards and regulatory requirements.
Previous Experience at Pfizer
Gregor Mac Mullen has extensive experience at Pfizer, where he held multiple positions over a span of 14 years. He served as Director of Operations Technology in Global Technology and Engineering from 2016 to 2020. Prior to that, he was the Associate Director of Operations Technology from 2006 to 2009. His earlier roles included Senior Manager of Technical Project Leader for Local Markets Access and Support from 2009 to 2016, and Manager of Product and Process Improvement from 2003 to 2006. His tenure at Pfizer provided him with a solid foundation in operations technology and project management.
Experience at Roche Molecular Systems
Before his time at Pfizer, Gregor Mac Mullen worked at Roche Molecular Systems as a Senior Scientist from 1993 to 2003. During this decade-long tenure, he developed expertise in scientific research and contributed to advancements in molecular systems. This experience laid the groundwork for his later roles in operations and technology within the pharmaceutical industry.
Expertise in Manufacturing Technologies
Gregor Mac Mullen specializes in aseptic biologics and generic sterile injectable manufacturing technologies and transfers. His expertise extends to managing contract manufacturing relationships and projects, which are critical for ensuring efficient production processes. His background in both scientific research and technical operations equips him with a comprehensive understanding of the complexities involved in pharmaceutical manufacturing.